 |
|
Benefits and Risks with Biologics and
Conventional Treatment for IBD
Relative Safety Versus Relative Risk |
|
Release Date: July 2007
|
|
Expiration Date: July 31, 2008
|
 |
|
Medical Crossfire Pod Pearls feature brief exchanges between a moderator and faculty members on important topics of interest to the practicing clinician. Pod Pearls CME-certified audio files can be listened to online or downloaded to an MP3 player. This format brings the clinical insights physicians have come to expect from Medical Crossfire to the busy clinician who needs to stay up-to-date on the implications of current knowledge on patient care.
Educational Overview
Treatment with biologic agents has improved outcomes for patients with inflammatory bowel diseases. While these treatments have safety concerns which clinicians must be aware of and address with their patients, the biologics have improved the achievement of remission or the maintenance of remission of disease for many patients. Thus, in making treatment decisions, clinicians must balance between safety and quality of life issues that may result from the choice of treatment for the patient. Finding this balance will be the focus of this Medical Crossfire Pod Pearl.
| At the conclusion of the activity, participants should be able to: |
| • |
Evaluate the available data regarding conventional therapies for patients with IBD.
|
| • |
Describe the evidence suggesting a potential benefit from early treatment of IBD with biologics.
|
Target Audience
This educational activity is designed for gastroenterologists and other health care professionals interested in or involved with the management of patients with Crohn’s disease or ulcerative colitis.
Method of Instruction
Participants should read the learning objectives and review the activity in its entirety. After reviewing the material, complete the activity evaluation online and receive your certificate immediately.
Alternatively, print out and fax the evaluation and you will receive a letter of credit awarding AMA PRA Category 1 Credit(s)TM three to four weeks after receipt of the evaluation.
Estimated time to complete this activity as designed is .5 hours.
Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of UMDNJ–Center for Continuing and Outreach Education and Medical Crossfire/Liberty Communications Network. UMDNJ–Center for Continuing and Outreach Education is accredited by the ACCME to provide continuing medical education for physicians.
UMDNJ–Center for Continuing and Outreach Education designates this educational activity for a maximum of 0.5
AMA PRA Category 1 Credits.TM Physicians should claim credit commensurate with the extent of their participation.
This Pod Pearl was peer-reviewed for relevance, accuracy of content and balance of presentation by
Steven R. Peikin, MD, and pilot-tested for time required for participation by Adam L. Palance, MD and
Michael Papper, MD.
Medical Crossfire® is a registered trademark of Liberty Communications Network.
Program Panel
| Panelists |
|
|
 |
|
Gary R. Lichtenstein, MD
Professor of Medicine
Gastrointestinal Division
Department of Medicine
University of Pennsylvania School of Medicine;
Director, Center for Inflammatory Bowel Diseases
University of Pennsylvania Health System
Philadelphia, Pennsylvania |
|
|
|
 |
|
Scott E. Plevy, MD
Associate Professor of Medicine
Division of Gastroenterology and Hepatology
University of North Carolina School of Medicine
Chapel Hill, North Carolina
|
|
|
|
| Moderator |
|
|
 |
|
Stephen B. Hanauer, MD
Professor of Medicine and Clinical Pharmacology
Director, Section of Gastroenterology, Hepatology
and Nutrition
University of Chicago Pritzker School of Medicine
Chicago, Illinois |
Academic Advisor
Steven R. Peikin, MD
Professor of Medicine
Head, Division of Gastroenterology and Liver Disease
University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School at Camden
The Cooper Hospital/University Medical Center
Camden, New Jersey
Disclosure Declarations
In accordance with the disclosure policies of UMDNJ and to conform with ACCME and FDA guidelines, individuals in a position to control the content of this education activity are required to disclose to the activity participants: 1) the existence of any financial interest or other relationships with proprietary entities producing health care goods or services, with the exemption of non-profit or government organizations and non-health care related companies, within the past 12 months; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device not yet approved.
Faculty Disclosure Delcarations
Dr. Hanauer has received grant/research support from Abbott Laboratories, Centocor, Inc., Elan Pharmaceuticals, Procter & Gamble Pharmaceuticals, Prometheus Labs, Salix Pharmaceuticals, Shire US, and UBC; has been a consultant for Abbott Labs, Centocor Inc., Elan Pharmaceuticals, Procter & Gamble Pharmaceuticals, Salix Pharmaceuticals, Shire US, and UCB; and has served on the speakers’ bureaus of Centocor, Inc., Procter & Gamble Pharmaceuticals, Salix Pharmaceuticals, and UCB.
Dr. Lichtenstein has received grant/research support from Abbott Laboratories, Berlex Laboratories, Celgene Corp., Celltech Pharmaceuticals, Centocor, Inc., Genetics Institute, Human Genome Sciences, InKine Pharmaceutical Co., Intesco, ISIS Corp., Millennium Pharmaceuticals, Otsuka America Pharmaceutical, Protein Design Labs, Protomed Scientific, and Salix Pharmaceuticals; has been a consultant for AstraZeneca Pharmaceuticals, Axcan Scandipharm, Celltech Pharmaceuticals, Centocor, Inc., Elan Pharmaceuticals, Faro Pharmaceuticals, Human Genome Sciences, GlaxoSmithKline Pharmaceuticals, Procter & Gamble Pharmaceuticals, Prometheus Labs, Protein Design Labs, Protomed Scientific, Salix Pharmaceuticals, Schering Corp., Serono, Shire US, Solvay Pharmaceuticals, Synta Pharmaceuticals, UCB, and Watson Pharmaceuticals; has served on the speakers’ bureaus of AstraZeneca Pharmaceuticals, Axcan Scandipharm, Centocor, Inc., Faro Pharmaceuticals, Proctor & Gamble Pharmaceuticals, Salix Pharmaceuticals, Schering Corp., Shire US, and Solvay Pharmaceuticals; and has received honoraria from Falk Pharma.
Dr. Plevy has received grant/research support from Callisto Pharmaceuticals, Centocor, Inc., Genentech, PDL BioPharma, and Synta Pharmaceuticals Corp.; has been a consultant for Abbott Laboratories, Berlex Laboratories, Callisto Pharmaceuticals, Celgene Corporation, Centocor, Inc., Dynogen Pharmaceuticals, Elan Pharmaceuticals, Genentech, Johnson & Johnson, Otsuka Pharmaceutical Co., PDL BioPharma, Prometheus Labs, Takeda Pharmaceuticals North America, Tanabe Seiyaku Co., and UCB; has received honoraria from Abbott Laboratories, Centocor, Inc., and PDL BioPharma; and has received royalties from Prometheus Labs.
Dr. Peikin has no relevant financial relationships to disclose.
Off-Label Usage Disclosure
This activity contains discussion of investigational uses of products, including adalimumab and certolizumab, not yet approved by the US FDA for the treatment of ulcerative colitis.
Disclaimer
The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of Centocor, any other manufacturer of pharmaceuticals, UMDNJ, or Medical Crossfire/Liberty Communications Network.
It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating panelist. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult the full prescribing information on any agent(s) presented in this activity for recommended dosage, indications, contraindications, warnings, precautions, and adverse effects before prescribing any medication.
Copyright © 2007 by UMDNJ–Center for Continuing and Outreach Education and Liberty Communications Network. All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems without permission in writing from UMDNJ–Center for Continuing and Outreach Education or Liberty Communications Network.
Medical Crossfire® is a registered trademark of Liberty Communications Network.
| For questions about downloading, please visit our FAQ section here |
Jointly Sponsored by the University of Medicine & Dentistry of New Jersey (UMDNJ)–Center for Continuing
and Outreach Education and Medical Crossfire®/Liberty Communications Network. |
 |
| This activity is supported by an educational grant from Centocor. |
|
|
|
